Exchange: NYSE·Updated 03:36 PM EDT
HAE logo

HAEHaemonetics Corp.

$75.33
$0.26
(0.35%)
Today
EarningsAug 6
Mkt Cap$3.41B
Vol375,945.00
News
all
press releases
Is it Apt to Retain Haemonetics Stock in Your Portfolio for Now?
HAE's Plasma franchise and NexSys PCS momentum may support growth, but heavy debt and competitive pressure remain key concerns.
Zacks
News Placeholder
More News
News Placeholder
Haemonetics Updates Financial Reporting Segments
Haemonetics Updates Financial Reporting Segments Haemonetics Updates Financial Reporting Segments PR Newswire BOSTON, June 5, 2026 BOSTON, June 5, 2026 /PRNewswire/ -- Haemonetics Corporation (NYSE: HAE), a global medical technology company focused on delivering innovative solutions designed to...
PR Newswire
News Placeholder
Haemonetics to Present at Goldman Sachs 47th Annual Global Healthcare Conference
Haemonetics to Present at Goldman Sachs 47th Annual Global Healthcare Conference Haemonetics to Present at Goldman Sachs 47th Annual Global Healthcare Conference PR Newswire BOSTON, June 2, 2026 BOSTON, June 2, 2026 /PRNewswire/ --Haemonetics Corporation (NYSE: HAE) announced that Chris Simon...
PR Newswire
News Placeholder
Haemonetics (HAE) Shares Cross Above 200 DMA
In trading on Friday, shares of Haemonetics Corp. (Symbol: HAE) crossed above their 200 day moving average of $62.24, changing hands as high as $65.84 per share. Haemonetics Corp. shares are currently trading up about 5.1% on the day. The chart below shows the one year perform...
Nasdaq News: Markets
News Placeholder
Investing in Haemonetics (HAE)? Don't Miss Assessing Its International Revenue Trends
Examine the evolution of Haemonetics' (HAE) overseas revenue trends and their effects on Wall Street's forecasts and the stock's prospects.
Zacks
News Placeholder
Is the Options Market Predicting a Spike in Haemonetics Stock?
Investors need to pay close attention to GBTG stock based on the movements in the options market lately.
Zacks
News Placeholder
HAE Stock Gains on Q4 Earnings & Revenue Beat, Gross Margin Cut
Haemonetics beats Q4 EPS and revenue estimates, shares rise 1.4%, but gross margin falls 120 basis points as the company sets its FY27 growth outlook.
Zacks
News Placeholder
Haemonetics Q4 Earnings Call Highlights
Haemonetics Q4 Earnings Call Highlights...
Yahoo! Finance: News
News Placeholder
Haemonetics (HAE) Q4 2026 Earnings Transcript
@media (max-width: 768px) { .image-container { width: 100% !important; float: none !important; margin: 0 0 1rem 0 !important; } } Image source: The Mo...
Nasdaq News: Markets
News Placeholder
Haemonetics (HAE) Reports Q4 Earnings: What Key Metrics Have to Say
Although the revenue and EPS for Haemonetics (HAE) give a sense of how its business performed in the quarter ended March 2026, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Zacks
<
1
2
...
>

Advertisement|Remove ads.